
PRGO — Perrigo Company PLC
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
$14.78
+$0.35 (+2.43%)
Perrigo Company PLC (PRGO) is a drug manufacturers - specialty & generic company listed on NYSE. It is led by Patrick Lockwood-Taylor, based in The Sharp Building, Dublin, Ireland, D02 TY74, with about 8,100 employees. Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Latest reported PRGO revenue for 2025-09-27 was $1.04B. Net income was $7.5M. Revenue was down 1.2% from 2025-06-28 to 2025-09-27. PRGO currently screens at market cap $1.48B.
Use this PRGO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PRGO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PRGO SEC filings page. Lician reads the product cache first so this HTML stays unique to Perrigo Company PLC even when a live quote feed is slow.
About Perrigo Company PLC
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
PRGO Key Statistics
Market Cap
$1.48B
Volume
2.60M
Previous Close
$14.48
Day Range
$14.38 – $14.79
EPS
-$1.25
Revenue
$4.37B
Net Income
-$171.80M
Gross Profit
$0.00
Free Cash Flow
$0.00
Dividend Yield
11.09%
Revenue Growth
-6.1%
Profit Margin
-3.9%
Employees
8,100
PRGO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $4.37B | $4.66B | $4.45B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$171.80M | -$12.70M | -$140.60M |
| EPS (Diluted) | -$1.25 | -$0.09 | -$1.04 |
Total Assets
$9.65B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
$362.90M
Free Cash Flow
$0.00
Perrigo Company PLC Company Information
- President, CEO & Director
- Patrick Lockwood-Taylor
- Headquarters
- The Sharp Building, Dublin, Ireland, D02 TY74
- Website
- www.perrigo.com
- Phone
- 353 1 709 4000
- IPO / Founded
- 1991-12-16
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic